Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H
Open Access
- 14 March 2018
- journal article
- review article
- Published by MDPI AG in Antibodies
- Vol. 7 (1) , 14
Abstract
Human application of monoclonal antibodies (mAbs), enzymes, as well as contrast media and many other particulate drugs and agents referred to as “nanomedicines”, can initiate pseudoallergic hypersensitivity reactions, also known as infusion reactions. These may in part be mediated by the activation of the complement system, a major humoral defense system of innate immunity. In this review, we provide a brief outline of complement activation-related pseudoallergy (CARPA) in general, and then focus on the reactions caused by mAb therapy. Because the alternative pathway of complement activation may amplify such adverse reactions, we highlight the potential use of complement factor H as an inhibitor of CARPA.Keywords
This publication has 34 references indexed in Scilit:
- Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responsesOncoImmunology, 2013
- Factor H: A Complement Regulator in Health and Disease, and a Mediator of Cellular InteractionsBiomolecules, 2012
- Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and preventionAdvanced Drug Delivery Reviews, 2011
- In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymersBiomaterials, 2011
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Anti-CD20 monoclonal antibodies: historical and future perspectivesHaematologica, 2009
- Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody TherapyThe Oncologist, 2008
- Tolerability and safety of rituximab (MabThera®)Cancer Treatment Reviews, 2005
- Expression of Complement Factor H by Lung Cancer CellsCancer Research, 2004
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002